by jlohrconsulting | Oct 9, 2025 | Uncategorized
Eur Spine J. 2025 Oct 9. doi: 10.1007/s00586-025-09438-z. Online ahead of print. NO ABSTRACT PMID:41065787 | DOI:10.1007/s00586-025-09438-z
by jlohrconsulting | Oct 9, 2025 | Uncategorized
J Neuroimmune Pharmacol. 2025 Oct 9;20(1):84. doi: 10.1007/s11481-025-10244-z. ABSTRACT Depression remains a major global health issue, characterized by inadequate response rates to conventional antidepressant therapies. This highlights a critical need for novel...
by jlohrconsulting | Oct 9, 2025 | Uncategorized
Metab Brain Dis. 2025 Oct 9;40(7):284. doi: 10.1007/s11011-025-01717-4. ABSTRACT Pharmacological treatments for major depressive disorder (MDD) have limited efficacy, underscoring the need for biomarkers to assess treatment response. Metabolomics enables...
by jlohrconsulting | Oct 9, 2025 | Uncategorized
Neurol Ther. 2025 Oct 9. doi: 10.1007/s40120-025-00828-5. Online ahead of print. ABSTRACT INTRODUCTION: Neurodegenerative dementia (ND) is characterized by progressive cognitive decline. The role of autoantibodies in ND remains controversial, as they may contribute to...
by jlohrconsulting | Oct 9, 2025 | Uncategorized
Res Child Adolesc Psychopathol. 2025 Oct 9. doi: 10.1007/s10802-025-01384-0. Online ahead of print. NO ABSTRACT PMID:41065994 | DOI:10.1007/s10802-025-01384-0
Recent Comments